Full-Time

Business Performance Manager

Updated on 7/25/2026

Deadline 9/30/26
Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

On-site role based in Hyderabad, Telangana, India.

Category
Business & Strategy (1)
Required Skills
Power BI
Python
Six Sigma
SQL
Tableau
VBA
Data Analysis
Excel/Numbers/Sheets

Get referred to Amgen

Find people who can refer or advise you

Requirements
  • Master’s degree and 6 years of relevant experience
  • Bachelor’s degree and 8 years of relevant experience
  • Associate’s degree and 12 years of relevant experience
  • Strong experience in process excellence, process improvement, process re-engineering, operational excellence, business transformation, business operations, or business performance management
  • Demonstrated hands-on experience using data analysis, automation, dashboards, and reporting tools to solve business problems, measure performance, identify opportunities, and improve decision-making
  • Experience with tools such as Excel, Power BI, Tableau, Smartsheet, Power Automate, Power Apps, VBA, SQL, Python, low-code/no-code platforms, workflow tools, or similar technologies
  • Ability to work through ambiguity and create structure where processes, data, ownership, or success measures are not clearly defined
  • Ability to work with imperfect data and develop pragmatic ways to generate insight, establish baselines, and measure improvement
  • Strong project execution skills, including scope definition, work planning, stakeholder management, action tracking, issue resolution, benefits delivery, and closure discipline
  • Self-starter with strong ownership, motivation, and discipline; able to independently plan work, maintain momentum, follow through on commitments, and deliver outcomes with limited day-to-day direction
  • Strong facilitation, communication, and influencing skills, with the ability to lead workshops, prepare leadership updates, and work effectively across functions and levels
  • Strong attention to detail, documentation discipline, and ability to maintain accurate records, track follow-ups, and ensure timely completion of required activities
  • Ability to combine a continuous improvement mindset with operational discipline, risk awareness, and readiness thinking
Responsibilities
  • Lead and execute process excellence, automation, process re-engineering, and business performance improvement projects from opportunity identification through implementation and benefits realization
  • Partner with site functions to assess current-state processes, identify pain points, map workflows, quantify inefficiencies, and design future-state processes that are simple, scalable, and effective
  • Apply structured improvement methods such as Lean, Six Sigma, Kaizen, root cause analysis, value stream mapping, customer /employee journey and process mapping to solve business problems and deliver measurable outcomes
  • Use hands-on data analysis, dashboards, reports, scorecards, and process metrics to diagnose issues, identify trends, establish baselines, monitor performance, and support leadership decision-making
  • Work effectively with fragmented, inconsistent, manual, incomplete, or unavailable data by establishing practical data collection approaches, proxy measures, or simple measurement systems
  • Identify and implement automation opportunities using relevant tools and platforms to reduce manual effort, improve data quality, increase process reliability, and enhance stakeholder experience
  • Create structure in ambiguous problem spaces by clarifying objectives, identifying stakeholders, defining success measures, organizing available information, and building clear execution plans
  • Facilitate workshops, stakeholder interviews, process design sessions, and problem-solving forums to align teams, make decisions, and drive action
  • Support site and business operational readiness for critical business processes, including process mapping, dependency identification, role clarity, continuity and recovery documentation, readiness exercises, lessons learned, and action tracking
  • Drive projects and improvement actions to closure with clear ownership, disciplined follow-through, stakeholder engagement, issue escalation, and benefits realization
  • Build strong relationships with site leadership, functional stakeholders, global partners, and enabling teams to understand priorities and convert them into actionable improvement plans
Desired Qualifications
  • Experience in Biotechnology, Pharmaceutical, Healthcare, Life Sciences, Global Capability Center, shared services, site operations, or regulated industry environments
  • Experience leading end-to-end process improvement, automation, analytics, business transformation, or operational excellence projects with measurable outcomes
  • Working knowledge of Lean, Six Sigma, Kaizen, value stream mapping, root cause analysis, process mining, workflow automation, or digital enablement methodologies
  • Lean Six Sigma Green Belt, PMP, Agile, Business Analysis, Data Analytics, Automation, Operational Excellence, or related certification
  • Hands-on experience with Power BI, Tableau, Smartsheet, Power Automate, Power Apps, Excel automation, SQL, Python, or similar analytics and automation tools
  • Experience supporting operational readiness, business resilience, risk management, crisis readiness, business continuity planning, recovery planning, process mapping, dependency analysis, readiness exercises, lessons learned, or action tracking
  • Strong customer-service mindset with the ability to act as a practical, solutions-oriented partner to site and global stakeholders

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs drive 70% of sales with 24% growth, offsetting patent cliff declines[1]
  • MariTide obesity candidate shows ~20% weight loss with improved dosing tolerability[1]
  • IMDYLLTRA approval as first T-cell engager for small cell lung cancer validates oncology pipeline[1]

What critics are saying

  • Tavneos withdrawal likely within 3–6 months due to FDA data manipulation, risking $500M/year revenue[1]
  • Corlanor and Sensipar Class II recalls signal manufacturing deviations, risking supply and reputation[1]
  • IRS audit dispute over 2016–2018 taxes could cost $100M+ and trigger credit rating downgrade[1]

What makes Amgen unique

  • Dual-pillar model fuses innovative biologics with a $3B biosimilars portfolio funding R&D[2]
  • Biology-first approach uses human genetics and AI to validate targets and accelerate discovery[2]
  • World-class agile biomanufacturing ensures high-quality delivery across 100 countries[2][5]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.